Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review.
Aleksandra KirillovaAnna LadoNataliya BlattPublished in: BioNanoScience (2022)
Coronavirus infection can have various degrees of severity and outcomes. In some cases, it causes excessive production of pro-inflammatory cytokines, a so-called cytokine storm, leading to acute respiratory distress syndrome. Unfortunately, the exact pathophysiology and treatment, especially for severe cases of COVID-19, are still uncertain. Results of preliminary studies showed that immunosuppressive therapy, such as interleukin (IL)-6, IL-1, and TNF-α antagonists commonly used in rheumatology, can be considered as treatment options for COVID-19, especially in severe cases. The review focused on the most common and currently studied monoclonal antibody drugs, as well as up-to-date data on the pathogenesis of COVID-19, host immune response against SARS-CoV-2 and its association with cytokine storm. It also covered effects of interleukin (IL)-6, IL-1, and TNF-α blockers on the course of coronavirus infection and outcome in patients treated for the main autoimmune disease and subsequently infected with COVID-19.
Keyphrases
- sars cov
- monoclonal antibody
- coronavirus disease
- respiratory syndrome coronavirus
- acute respiratory distress syndrome
- immune response
- rheumatoid arthritis
- extracorporeal membrane oxygenation
- multiple sclerosis
- drug induced
- early onset
- stem cells
- insulin resistance
- inflammatory response
- systemic lupus erythematosus
- dendritic cells
- electronic health record
- adipose tissue
- density functional theory
- molecular dynamics
- glycemic control